The AI-based in vitro diagnostic medical device startup Noul was selected as a project to support the RIGHT Fund's program.

 

Noul's miLab (Micro-Intelligent Laboratory) enables rapid and accurate diagnosis with a fully automated platform for microscopic reading, which is a standard for diagnosis of malaria, from blood sample preparation to analysis.

 

Through this opportunity, Noul is given a momentum to strengthen AI learning necessary to distinguish between Plasmodium falciparum and Plasmodium vivax with miLab.



 

RIGHT Fund has a joint partnership with the Ministry of Health and Welfare, Korean life science companies (SK Bioscience, LG Chem, GC Pharma, Chong Kun Dang Holdings, Genexine, Bioneer, EuBiologics, SD Biosensor) and Bill & Melinda Gates Foundation to promote global public health. This is a global public-private partnership research fund. RIGHT Fund discovers, selects and supports R&D of vaccines, treatments, diagnostics, and digital health technologies that has high technologies from Korean companies to support Korea's excellent healthcare effectively contribute to the endemic and respond to new infectious diseases in developing countries.

 

There are four types of malaria that can cause infection to humans. Of these, tropical thermal malaria has a high mortality rate that can lead to death if not properly treated from the beginning. As for Tri-day fever malaria has a relatively low mortality rate, but for a long period of time due to fever, headache, abdominal pain, etc.



Newsletter Sign Up

By clicking "submit," you agree to receive emails from Bron2Global and accept our web terms of use and privacy and cookie policy*Terms apply.